Altimmune (ALT) Common Equity (2010 - 2026)

Altimmune (ALT) has 17 years of Common Equity data on file, last reported at $284.0 million in Q1 2026.

• On a quarterly basis, Common Equity rose 99.76% year-over-year to $284.0 million in Q1 2026; TTM through Mar 2026 was $284.0 million, a 99.76% increase from a year earlier, with the FY2025 full-year figure at $224.9 million, up 82.09% from the prior year.
• Common Equity for Q1 2026 stood at $284.0 million, up from $224.9 million in the prior quarter.
• Over the last five years, Common Equity for ALT reached as high as $284.0 million in Q1 2026 and fell as low as $123.5 million in Q4 2024.
• Historically, Common Equity has averaged $178.2 million across 5 years, with a median of $172.9 million in 2024.
• Across the five-year window, Common Equity slumped 36.37% in 2024 and soared 99.76% in 2026, its largest moves.
• Year by year, Common Equity stood at $185.3 million in 2022, then gained by 4.75% to $194.1 million in 2023, then slumped by 36.37% to $123.5 million in 2024, then surged by 82.09% to $224.9 million in 2025, then climbed by 26.28% to $284.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $284.0 million in Q1 2026, $224.9 million in Q4 2025, and $185.6 million in Q3 2025.